ReviewCureus2026
Epithelial-Mesenchymal Transitional Markers in Endometrial Carcinoma: A Review of Clinicopathological Correlation.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinoma is the most frequently diagnosed gynaecological malignancy in developed countries, and its global incidence continues to increase. Myometrial invasion and lymphovascular spread, driven by epithelial-mesenchymal transition (EMT), are among the most important determinants of clinical outcome. EMT is a dynamic biological process in which epithelial cells develop migratory and invasive mesenchymal characteristics under the influence of transcription factors including SNAIL (SNAI1), SLUG (SNAI2), TWIST, and ZEB2. The aims of this review are to review the current evidence on the immunohistochemical (IHC) expression of the four important EMT transcription factors (SLUG, TWIST, SNAIL, and ZEB2) in endometrial carcinoma and to focus on their clinicopathological correlations, prognostic implications, signalling mechanisms, and potential as therapeutic targets. We conducted a narrative review of the published literature in English using the PubMed, Scopus, and Google Scholar databases. We retrieved and reviewed articles on IHC or molecular expression of SLUG, TWIST, SNAIL, and ZEB2 in endometrial carcinoma. SLUG overexpression independently predicted the advanced International Federation of Gynecology and Obstetrics (FIGO) stage, deep myometrial invasion, lymphovascular space invasion (LVSI), and poorer five-year survival. TWIST expression showed a significant association with the depth of myometrial invasion and loss of E-cadherin expression and was also found to be an independent prognostic factor in multivariate analysis. SNAIL correlates with histological grade, peritoneal cytology positivity, and non-endometrioid histology. High levels of ZEB2 are related to adnexal involvement and higher FIGO stage. Together, these four markers represent a prognostically relevant panel of markers reflecting the invasive phenotype of endometrial carcinoma, which might be targets for novel therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.